edaravone has been researched along with Colonic Inertia in 1 studies
Colonic Inertia: Symptom characterized by the passage of stool once a week or less.
Excerpt | Relevance | Reference |
---|---|---|
"An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS)." | 9.69 | Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. ( Aoki, M; Apple, S; Bidani, S; Couratier, P; Genge, A; Hirai, M; Jackson, CE; Kalin, A; Lunetta, C; Pattee, GL; Petri, S; Sakata, T; Salah, A; Selness, D; Sobue, G; Wamil, A; Yoshino, H, 2023) |
"An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS)." | 5.69 | Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. ( Aoki, M; Apple, S; Bidani, S; Couratier, P; Genge, A; Hirai, M; Jackson, CE; Kalin, A; Lunetta, C; Pattee, GL; Petri, S; Sakata, T; Salah, A; Selness, D; Sobue, G; Wamil, A; Yoshino, H, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Genge, A | 2 |
Pattee, GL | 2 |
Sobue, G | 2 |
Aoki, M | 2 |
Yoshino, H | 2 |
Couratier, P | 2 |
Lunetta, C | 2 |
Petri, S | 2 |
Selness, D | 2 |
Bidani, S | 2 |
Hirai, M | 2 |
Sakata, T | 2 |
Salah, A | 2 |
Apple, S | 2 |
Wamil, A | 2 |
Kalin, A | 2 |
Jackson, CE | 2 |
1 trial available for edaravone and Colonic Inertia
Article | Year |
---|---|
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Constipation; Edaravone; Female; Humans; Male; | 2023 |